STOCK TITAN

Gritstone Bio Inc - GRTS STOCK NEWS

Welcome to our dedicated news page for Gritstone Bio (Ticker: GRTS), a resource for investors and traders seeking the latest updates and insights on Gritstone Bio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Gritstone Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Gritstone Bio's position in the market.

Rhea-AI Summary
Gritstone bio, Inc. (Nasdaq: GRTS) is adjusting the timeline for the Phase 2b trial of its next-generation COVID-19 vaccine to Fall 2024 to incorporate fully GMP-grade raw materials, enhancing regulatory value and study interpretability. The company aims to address the latest seasonal variant and express gratitude to FDA and BARDA for their support.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial covid-19
-
Rhea-AI Summary
Gritstone bio, Inc. (Nasdaq: GRTS) announced the granting of nonqualified stock options to six employees to purchase 147,000 shares of its common stock. The options have an exercise price of $2.26 and will vest over a four-year period, subject to the employees' continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
none
-
Rhea-AI Summary
Gritstone bio, Inc. (Nasdaq: GRTS) announced their participation in B. Riley Securities' 4th Annual Oncology Conference. The event will feature a fireside chat with Andrew Allen, Co-founder, President, and CEO, discussing the company's work in developing potent vaccines. The webcast will be available live and archived for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary
Gritstone bio, a clinical-stage biotechnology company (Nasdaq: GRTS), granted two employees nonqualified stock options to purchase 18,500 shares of its common stock at an exercise price of $2.10. The options will vest over a four-year period, subject to the employees’ continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.24%
Tags
none
-
Rhea-AI Summary
Gritstone bio, Inc. (Nasdaq: GRTS) announced the grant of nonqualified stock options to four employees to purchase 42,000 shares of its common stock at an exercise price of $1.53, in line with Nasdaq Listing Rule 5635(c)(4). The options will vest over a four-year period, with 25% vesting on the first anniversary of hire, and 1/48th vesting monthly thereafter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.47%
Tags
none
-
Rhea-AI Summary
Gritstone bio, Inc. (Nasdaq: GRTS) will be participating in investor conferences, including the 6th Annual Evercore ISI HealthCONx Conference, 35th Annual Piper Sandler Healthcare Conference, and First Annual Goldman Sachs Catalyst Clinic. The company's Co-founder, President, and CEO, Andrew Allen, M.D., Ph.D., will be speaking at these events. Live webcasts will be available via https://ir.gritstonebio.com/investors/events, with archived replays accessible for 30 days after each event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.94%
Tags
conferences
Rhea-AI Summary
Gritstone Bio, Inc. (Nasdaq: GRTS) reports financial results for Q3 2023 and recent updates on its COVID-19 prevention and cancer vaccine programs. The company has received a BARDA contract for a Phase 2b study comparing its samRNA vaccine candidate to an approved COVID-19 vaccine. Preliminary data from Phase 2 of its GRANITE cancer vaccine study are expected in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.69%
Tags
earnings
-
Rhea-AI Summary
Gritstone bio, Inc. (Nasdaq: GRTS) announces grant of nonqualified stock options to new employee, part of inducement to join, with exercise price of $1.83 and vesting over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.65%
Tags
none
-
Rhea-AI Summary
Gritstone bio presents results from Phase 1 studies of its self-amplifying mRNA vaccine candidates against COVID-19 at IDWeek 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.53%
Tags
covid-19
Rhea-AI Summary
Gritstone bio grants stock options to employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
none
Gritstone Bio Inc

Nasdaq:GRTS

GRTS Rankings

GRTS Stock Data

202.13M
87.18M
2.59%
44.84%
9.43%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Emeryville

About GRTS

gritstone oncology is a cancer immunotherapy company developing next-generation personalized cancer therapeutics. gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors, and very deep financial backing to tackle fundamental challenges at the intersection of cancer biology, immunology, and immunotherapy design. the company’s initial goal is to identify and deploy therapeutic neo-antigens from individual patients’ tumors to develop novel treatments for lung cancer. gritstone oncology is headquartered in the san francisco bay area with certain key functions located in cambridge, ma. gritstone oncology launched in october 2015 with a series a financing of $102 million.